A third evaluation of tertiary cytoreduction

Journal of Surgical Oncology

Volumn 98, Issue 7, 2008, Pages 530-534

  Gultekin, Murat ^a,d   Velipaşaoǧlu, Melih ^b   Aksan, Guldeniz ^b   Dursun, Polat ^c   Dogan, Nasuh Utku ^b   Yuce, Kunter ^b   Ayhan, Ali ^c  

^a Cankiri Government Hospital   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

^d NONE   (Turkey)

Author keywords

Debulking surgery; Prognosis; Recurrent epithelial ovarian carcinoma; Recurrent ovarian cancer; Tertiary cytoreduction

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; TAMOXIFEN; TOPOTECAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; ASCITES; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MEDICAL RECORD REVIEW; METASTASIS; MORBIDITY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 56649116094     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21146     Document Type: Article

References (16)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. Cancer J Clin 2004;54:8-29.
2. Heintz AP, Odicino F, Maisonneuve P, et al.: Carcinoma of the ovary. J Epidemiol Biostat 2001;6:107-138.
3. Bristow RE, Tomacruz RS, Armstrong DK, et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248-1259.
4. Eisenkop SM, Friedman RL, Wang HJ: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol 1998;69:103-108.
5. Ayhan A, Gultekin M, Dursun P, et al.: Predictors and outcomes of recurrent disease after a negative second look laparotomy. Surg Oncol 2007.
6. Chi DS, Palayekar MJ, Sonoda Y, et al.: Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. Gynecol Oncol 2007.
7. Vasey PA, Jayson GC, Gordon A, et al.: Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-1691.
8. Ozols RF, Bundy BN, Greer BE, et al.: Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-3200.
9. Hoskins WJ, McGuire WP, Brady MF, et al.: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 974-979; discussion 979-80.
10. Ayhan A, Gultekin M, Taskiran C, et al.: The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol 2006;194:49-56.
11. Munkarah AR, Coleman RL: Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 2004;5:273-280.
12. Scarabelli C, Gallo A, Carbone A: Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001;83:504-512.
13. Gadducci A, Iacconi P, Cosio S, et al.: Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000;79:344-349.
14. Eisenkop SM, Friedman RL, Spirtos NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88:144-153.
15. Leitao MM, Jr., Kardos S, Barakat RR, et al.: Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol 2004;95:181-188.
16. Karam AK, Santillan A, Bristow RE, et al.: Tertiary cytoreductive surgery in recurrent ovarian cancer: Selection criteria and survival outcome. Gynecol Oncol 2007;104:377-380.